Moonlake Immunotherapeutics operates as a clinical-stage biotechnology company. The company is headquartered in Zug, Zug and currently employs 100 full-time employees. The company went IPO on 2020-10-20. The Firm is a clinical-stage biopharmaceutical company focused on the development of medicines for immunologic diseases, including inflammatory skin and joint diseases. The firm develops tri-specific nanobody Sonelokimab (SLK) which purpose is to target and penetrate difficult-to-reach inflamed tissues. SLK is a molecule with enhanced enrichment in deep skin & joints and binding of targets. SLK inhibits IL-17A and IL-17F inhibition to treat inflammatory diseases, by independently inhibiting the naturally-occurring IL-17 A/A, A/F and F/F dimers that drive inflammation in patients.
Follow-Up Questions
MoonLake Immunotherapeutics 'in CEO'su kimdir?
Dr. Jorge Santos Da Silva 2022 'den beri şirketle birlikte olan MoonLake Immunotherapeutics 'in Chief Executive Officer 'ıdır.
MLTX hissesinin fiyat performansı nasıl?
MLTX 'in mevcut fiyatı $54.16 'dir, son işlem günde 0% decreased etti.
MoonLake Immunotherapeutics için ana iş temaları veya sektörler nelerdir?
MoonLake Immunotherapeutics Biotechnology endüstrisine ait ve sektör Health Care 'dir
Wall Street analistlerine göre, 17 analist MoonLake Immunotherapeutics için analist derecelendirmeleri gerçekleştirdi, bunlar 11 güçlü al, 11 al, 2 tut, 0 sat ve 11 güçlü sat içermektedir
